SG10201903161XA - Methods for production and uses of multipotent cell populations - Google Patents

Methods for production and uses of multipotent cell populations

Info

Publication number
SG10201903161XA
SG10201903161XA SG10201903161XA SG10201903161XA SG10201903161XA SG 10201903161X A SG10201903161X A SG 10201903161XA SG 10201903161X A SG10201903161X A SG 10201903161XA SG 10201903161X A SG10201903161X A SG 10201903161XA SG 10201903161X A SG10201903161X A SG 10201903161XA
Authority
SG
Singapore
Prior art keywords
methods
cell populations
production
multipotent
hiv
Prior art date
Application number
SG10201903161XA
Inventor
Christopher Reid
Original Assignee
Christopher Reid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Christopher Reid filed Critical Christopher Reid
Publication of SG10201903161XA publication Critical patent/SG10201903161XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Abstract

Methods for production and uses of multipotent cell populations The claimed invention is directed towards the generation of pluripotent, multipotent, and/or self-renewing cells which are capable of beginning to differentiate in culture into a variety of cell types and capable of further differentiation in vivo. The claimed invention is also directed towards the generation of desirable, differentiating cell populations transplantable to patients, genetic modification of endogenous cells, and the treatment of patients suffering from diseases that may be ameliorated by these methods. This invention also provides methods for preventing, treating, or retarding disease related to immunodeficiency virus (e.g. HIV-I, HIV-2, SIV, FIV, etc.) infection. Drawing to accompany the abstract (for publication purposes): No Suitable Figure
SG10201903161XA 2007-05-29 2008-05-28 Methods for production and uses of multipotent cell populations SG10201903161XA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US93202007P 2007-05-29 2007-05-29
US93313307P 2007-06-05 2007-06-05
US93367007P 2007-06-08 2007-06-08
US644908P 2008-01-14 2008-01-14
US6476108P 2008-03-25 2008-03-25

Publications (1)

Publication Number Publication Date
SG10201903161XA true SG10201903161XA (en) 2019-05-30

Family

ID=40094346

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201509679XA SG10201509679XA (en) 2007-05-29 2008-05-28 Methods for production and uses of multipotent cell populations
SG10201903161XA SG10201903161XA (en) 2007-05-29 2008-05-28 Methods for production and uses of multipotent cell populations

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201509679XA SG10201509679XA (en) 2007-05-29 2008-05-28 Methods for production and uses of multipotent cell populations

Country Status (15)

Country Link
US (1) US20110217274A1 (en)
EP (2) EP3128015A3 (en)
JP (2) JP2010528613A (en)
CN (2) CN101772580B (en)
AU (1) AU2008260187A1 (en)
BR (1) BRPI0810949A2 (en)
CA (1) CA2725953A1 (en)
ES (1) ES2612538T3 (en)
HU (1) HUE030872T2 (en)
IL (2) IL202401A (en)
PL (1) PL2164993T3 (en)
PT (1) PT2164993T (en)
RU (2) RU2535365C2 (en)
SG (2) SG10201509679XA (en)
WO (1) WO2008150814A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
EP4223769A3 (en) 2005-12-13 2023-11-01 Kyoto University Nuclear reprogramming factor
EP2137296A2 (en) 2007-03-23 2009-12-30 Wisconsin Alumni Research Foundation Somatic cell reprogramming
US11859168B2 (en) * 2007-05-29 2024-01-02 Christopher B. REID Electroporation, developmentally-activated cells, pluripotent-like cells, cell reprogramming and regenerative medicine
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
JP2008307007A (en) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag Human pluripotent stem cell induced from human tissue-originated undifferentiated stem cell after birth
JP5346925B2 (en) 2008-05-02 2013-11-20 国立大学法人京都大学 Nuclear initialization method
AU2009256202B2 (en) 2008-06-04 2014-07-03 FUJIFILM Cellular Dynamics, Inc. Methods for the production of IPS cells using non-viral approach
JP2012500005A (en) * 2008-08-12 2012-01-05 セルラー ダイナミクス インターナショナル， インコーポレイテッド Method for generating iPS cells
JP2010148440A (en) * 2008-12-25 2010-07-08 Japan Health Science Foundation System for quickly constructing recombinant adenovirus
EP2425001A4 (en) * 2009-04-30 2012-11-14 Univ California Combination anti-hiv vectors, targeting vectors, and methods of use
US9365866B2 (en) * 2009-06-03 2016-06-14 National Institute Of Advanced Industrial Science And Technology Vectors for generating pluripotent stem cells and methods of producing pluripotent stem cells using the same
US9453205B2 (en) * 2009-10-31 2016-09-27 Genesis Technologies Limited Methods for reprogramming cells and uses thereof
CN102947444A (en) * 2010-06-23 2013-02-27 帷幄生物技术公司 Compositions and methods for re-programming cells without genetic modification for treatment of cardiovascular diseases
EP2625272B1 (en) 2010-10-08 2015-09-16 Mina Therapeutics Limited Methods of inducing insulin production
WO2012061075A2 (en) * 2010-10-25 2012-05-10 The Regents Of The University Of California Hiv resistant and functional hematopoietic stem/progenitor cells and macrophages from induced pluripotent stem cells
JP6073795B2 (en) * 2010-10-27 2017-02-01 カッパーアールエヌエー，インコーポレイテッド Treatment of IFRD1-related diseases by inhibition of natural antisense transcripts to interferon-related developmental regulator 1 (IFRD1)
JP6073916B2 (en) * 2011-12-05 2017-02-01 ファクター バイオサイエンス インコーポレイテッド Methods and products for transfecting cells
CN102659951A (en) * 2012-05-29 2012-09-12 西安医学院 TAT (Trans-activating factor) kringle domain-modified nenurogenin2 fusion protein, as well as preparation method thereof and application thereof
WO2014035433A1 (en) * 2012-08-31 2014-03-06 Jan Nolta Genetically modified msc and therapeutic methods
US9663564B2 (en) 2013-03-15 2017-05-30 The Regents Of The University Of California Vectors and methods to treat ischemia
US20140065110A1 (en) 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
CA2930973A1 (en) 2013-11-22 2015-05-28 Pal SAERTROM C/ebp alpha short activating rna compositions and methods of use
EP3268480B1 (en) * 2015-03-09 2021-05-19 Sinai Health System Tools and methods for using cell division loci to control proliferation of cells
KR20180032586A (en) * 2015-07-02 2018-03-30 메디젠, 인크. Recombinant virus-like particles using the Bacillus immunodeficiency virus GAG protein
JP6890831B2 (en) * 2015-07-08 2021-06-18 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド HIV preimmunization and immunotherapy
JP6841609B2 (en) 2015-07-10 2021-03-10 ３スキャン インコーポレイテッド Spatial multiplexing of histological staining
TWI808934B (en) 2015-12-31 2023-07-21 美商伯克利之光生命科技公司 Tumor infilitrating cells engineered to express a pro-inflammatory polypeptide
EP3429753A4 (en) * 2016-03-16 2019-11-06 Berkeley Lights, Inc. Methods, systems and devices for selection and generation of genome edited clones
EP3463417A4 (en) * 2016-06-03 2020-04-01 Hough Ear Institute Combination therapies for inner ear sensory hair cell regeneration/replacement
CN106086075B (en) * 2016-06-23 2019-08-06 福建医科大学 The construction method of CXCR4RNAi slow virus carrier
JP7312695B2 (en) * 2016-07-19 2023-07-21 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Oncolytic virus targeting STAT3
CN106497882A (en) * 2016-10-29 2017-03-15 复旦大学 The cell strain of overexpression R spondin1 and Noggin and its construction method and application simultaneously
AU2017388874A1 (en) 2016-12-30 2019-07-18 Berkeley Lights, Inc. Methods for selection and generation of genome edited T cells
CN108977463A (en) * 2017-05-31 2018-12-11 伯仕利生物科技发展（盐城）有限公司 A kind of technical method for inhibiting production to be broken up with stem cell
US20210363486A1 (en) 2018-02-09 2021-11-25 Kyoto University Cardiomyocyte proliferation promoting agent and use thereof
US20210095258A1 (en) * 2018-02-22 2021-04-01 Celularity Inc. Post partum tissue-derived induced pluripotent stem cells and uses thereof
CN108715868A (en) * 2018-05-31 2018-10-30 深圳市免疫基因治疗研究院 A kind of Gaucher slow virus carriers, slow virus and its preparation method and application
CN111484977B (en) * 2019-01-25 2023-05-16 中国科学院脑科学与智能技术卓越创新中心 Method of reprogramming to produce functional noradrenergic neurons
CN110283779A (en) * 2019-07-17 2019-09-27 吉林省农业科学院 A kind of isolated culture method and culture medium of chicken embryonic stem cells
KR20230123926A (en) * 2020-09-29 2023-08-24 뉴엑셀 테라퓨틱스 아이엔씨. DLX2 vectors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2395698A (en) 1943-12-18 1946-02-26 Walter J Mathieu Electric switch
US4361552A (en) 1980-09-26 1982-11-30 Board Of Regents, The University Of Texas System Wound dressing
US5032508A (en) 1988-09-08 1991-07-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US4956178A (en) 1988-07-11 1990-09-11 Purdue Research Foundation Tissue graft composition
US4902508A (en) 1988-07-11 1990-02-20 Purdue Research Foundation Tissue graft composition
JP2710967B2 (en) * 1988-11-22 1998-02-10 株式会社日立製作所 Manufacturing method of integrated circuit device
US7479269B2 (en) 1988-11-23 2009-01-20 Genetics Institute, Llc Methods for selectively enriching TH1 and TH2 cells
US5281422A (en) 1991-09-24 1994-01-25 Purdue Research Foundation Graft for promoting autogenous tissue growth
US5453357A (en) 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
DE69434447T2 (en) 1993-06-07 2006-05-18 Vical, Inc., San Diego PLASMIDE FOR GENE THERAPY
US6217867B1 (en) 1993-09-13 2001-04-17 University Of Pittsburgh Non-lethal methods for conditioning a recipient for bone marrow transplantation
US6432711B1 (en) 1993-11-03 2002-08-13 Diacrin, Inc. Embryonic stem cells capable of differentiating into desired cell lines
US5928944A (en) 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
US5484720A (en) 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
WO1996017073A1 (en) 1994-11-29 1996-06-06 Takara Shuzo Co., Ltd. Process for producing transformed cell
US5554389A (en) 1995-04-07 1996-09-10 Purdue Research Foundation Urinary bladder submucosa derived tissue graft
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
GB9518606D0 (en) * 1995-09-12 1995-11-15 Inst Of Psychiatry Neural transplantation
US5783566A (en) 1996-05-10 1998-07-21 California Institute Of Technology Method for increasing or decreasing transfection efficiency
ES2306841T3 (en) 1996-08-23 2008-11-16 Cook Biotech, Inc. PROTESIS FOR COLEGENE BASED GRAFT.
EP0946186B1 (en) 1996-12-10 2003-03-26 Purdue Research Foundation Stomach submucosa derived tissue graft
WO1998046165A1 (en) 1997-04-11 1998-10-22 Cryolife, Inc. Tissue decellularization
ES2245042T3 (en) * 1997-09-24 2005-12-16 The Regents Of The University Of California VECTORS OF NON-PRIMATE LENTIVIRUS AND PACKAGING SYSTEMS.
US6734018B2 (en) 1999-06-07 2004-05-11 Lifenet Process for decellularizing soft-tissue engineered medical implants, and decellularized soft-tissue medical implants produced
CA2377371A1 (en) 1999-06-22 2000-12-28 David N. Herndon Enhanced wound coverage to enhance wound healing
US6479064B1 (en) 1999-12-29 2002-11-12 Children's Medical Center Corporation Culturing different cell populations on a decellularized natural biostructure for organ reconstruction
US6376244B1 (en) 1999-12-29 2002-04-23 Children's Medical Center Corporation Methods and compositions for organ decellularization
EP1315796B1 (en) 2000-08-16 2006-07-12 Duke University Decellularized tissue engineered constructs and tissues
US6733993B2 (en) * 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
AU2001292917A1 (en) 2000-09-20 2002-04-02 Regeneration Technologies, Inc. Method of preparing and processing transplant tissue
US6995013B2 (en) 2002-07-08 2006-02-07 Biomed Solutions, Llc Cell-scaffold composition containing five layers
US7211247B2 (en) 2001-04-09 2007-05-01 University Of Southern California Lentivirus vectors for gene transfer to alveolar epithelial cells
WO2003002165A1 (en) 2001-06-28 2003-01-09 Cook Biotech Incorporated Graft prosthesis devices containing renal capsule collagen
US6800753B2 (en) 2001-09-04 2004-10-05 University Of Iowa Research Foundation Regenerated cellulose and oxidized cellulose membranes as potential biodegradable platforms for drug delivery and tissue engineering
US20030109037A1 (en) * 2001-09-24 2003-06-12 Reid Christopher Brian Methods for application of genetically-modified endogenous or exogenous stem/progenitor or their progeny for treatment of disease
US20030099621A1 (en) 2001-11-29 2003-05-29 Robert Chow Stem cell screening and transplantation therapy for HIV infection
US7297540B2 (en) 2002-01-15 2007-11-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of generating tissue using devitalized, acellular scaffold matrices derived from micro-organs
AU2003211066A1 (en) 2002-02-19 2003-09-09 Bioarttis, Inc. Artificial vessel scaffold and artificial organs therefrom
US7763722B2 (en) * 2003-01-17 2010-07-27 University Of Florida Research Foundation, Inc. Small interference RNA gene therapy
KR101376013B1 (en) 2005-08-26 2014-03-19 리전츠 오브 더 유니버스티 오브 미네소타 Decellularization and recellularization of organs and tissues
EP4223769A3 (en) * 2005-12-13 2023-11-01 Kyoto University Nuclear reprogramming factor

Also Published As

Publication number Publication date
EP3128015A2 (en) 2017-02-08
PL2164993T4 (en) 2017-08-31
IL202401A (en) 2015-10-29
EP3128015A3 (en) 2017-05-03
WO2008150814A3 (en) 2009-02-05
JP2015077132A (en) 2015-04-23
IL241906A0 (en) 2015-11-30
EP2164993B1 (en) 2016-09-21
CN105586358B (en) 2020-08-25
EP2164993A2 (en) 2010-03-24
RU2718536C2 (en) 2020-04-08
SG10201509679XA (en) 2015-12-30
BRPI0810949A2 (en) 2015-10-27
RU2014139904A3 (en) 2018-06-28
ES2612538T3 (en) 2017-05-17
CN105586358A (en) 2016-05-18
CA2725953A1 (en) 2008-12-11
AU2008260187A1 (en) 2008-12-11
EP2164993A4 (en) 2011-04-13
JP2010528613A (en) 2010-08-26
WO2008150814A8 (en) 2009-07-30
CN101772580B (en) 2015-11-25
PL2164993T3 (en) 2017-08-31
WO2008150814A2 (en) 2008-12-11
HUE030872T2 (en) 2017-06-28
CN101772580A (en) 2010-07-07
RU2009148666A (en) 2011-07-10
US20110217274A1 (en) 2011-09-08
RU2535365C2 (en) 2014-12-10
PT2164993T (en) 2017-01-12
IL202401A0 (en) 2011-08-01
RU2014139904A (en) 2016-04-20
IL241906B (en) 2021-07-29

Similar Documents

Publication Publication Date Title
SG10201903161XA (en) Methods for production and uses of multipotent cell populations
NZ596162A (en) Pharmaceutical composition for the treatment of heart diseases
GB2434157A (en) Platelets from stem cells
AU2012274478A8 (en) Method for amplifying NK cells
WO2011130675A3 (en) Dopaminergic neurons differentiated from pluripotent stem cells and uses of thereof
AU2009240884A8 (en) Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation
EP2548950A3 (en) Reprogramming T cells and hematopoietic cells
WO2011139628A8 (en) Generation of anterior foregut endoderm from pluripotent cells
WO2012061075A3 (en) Hiv resistant and functional hematopoietic stem/progenitor cells and macrophages from induced pluripotent stem cells
EP2732819A3 (en) Compounds that enhance Atoh-1 expression
MX2010001353A (en) Population of adult stem cells derived from cardiac adipose tissue and use thereof in cardiac regeneration.
TN2011000628A1 (en) Production of polio virus at high titres for vaccine production
NZ609731A (en) Compositions of adult organ stem cells and uses thereof
WO2010108005A3 (en) Novel neural progenitors from pluripotent stem cells, methods of producing same and use to produce neural cells
CY1118073T1 (en) COMPOSITIONS AND METHODS FOR INCREASING THE TELECOMMUNICATION ACT
WO2008056368A3 (en) Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases
MX340185B (en) Bone marrow derived cd271 precursor cells for cardiac repair.
WO2010082787A3 (en) Pharmaceutical composition for bone-disease treatment or countering inflammation, comprising cartilage stem cells as an active principle
NZ593365A (en) Pharmaceutical preparation comprising a blood mononuclear cell culture
WO2012106367A3 (en) Pluripotent stem cells and method of stimulating and extracting non-embryonic pluripotent stem cells from mammal blood and using reconstituted pluripotent stem cells to treat diseases including chronic obstructive pulmonary disease
Hacke et al. Genetic modification of mouse bone marrow by lentiviral vector-mediated delivery of hypoxanthine-Guanine phosphoribosyltransferase short hairpin RNA confers chemoprotection against 6-thioguanine cytotoxicity
WO2012075462A3 (en) Methods and compositions for treatment of muscular dystrophy
WO2008126039A3 (en) Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods
Sun et al. 5-Azacytidine-induced cardiomyocyte differentiation of very small embryonic-like stem cells
MX2008015392A (en) Treatment of ischemic disease using erythropoietin.